Publications
Found 5 results
Filters: Author is L.P. Wang [Clear All Filters]
“Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia”, vol. 14, pp. 4896-4902, 2015.
, “Identification of SNPs within the PRLR gene and effects on maternal behavior in sheep”, vol. 14, pp. 17536-17543, 2015.
, “mRNA expression of prolactin receptor in sheep pituitary and its effect on maternal behavior”, vol. 14, pp. 8650-8657, 2015.
, “Limitation of high-resolution melting curve analysis for genotyping simple sequence repeats in sheep”, vol. 13, pp. 2645-2653, 2014.
, “Association between PPARγ2 Pro12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China”, vol. 11, pp. 2929-2938, 2012.
,
Akiyama TE, Sakai S, Lambert G, Nicol CJ, et al. (2002). Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. 22: 2607-2619.
http://dx.doi.org/10.1128/MCB.22.8.2607-2619.2002
PMid:11909955 PMCid:133709
Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, et al. (2000). The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26: 76-80.
http://dx.doi.org/10.1038/79216
PMid:10973253
Beamer BA, Yen CJ, Andersen RE, Muller D, et al. (1998). Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47: 1806-1808.
http://dx.doi.org/10.2337/diabetes.47.11.1806
PMid:9792554
Black MH, Fingerlin TE, Allayee H, Zhang W, et al. (2008). Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57: 1048-1056.
http://dx.doi.org/10.2337/db07-0848
PMid:18162503
Bouhlel MA, Derudas B, Rigamonti E, Dievart R, et al. (2007). PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6: 137-143.
http://dx.doi.org/10.1016/j.cmet.2007.06.010
PMid:17681149
Danawati CW, Nagata M, Moriyama H, Hara K, et al. (2005). A possible association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 gene with obesity in native Javanese in Indonesia. Diabetes Metab. Res. Rev. 21: 465-469.
http://dx.doi.org/10.1002/dmrr.543
PMid:15739197
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, et al. (1998). A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20: 284-287.
http://dx.doi.org/10.1038/3099
PMid:9806549
Ghoussaini M, Meyre D, Lobbens S, Charpentier G, et al. (2005). Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 6: 11.
http://dx.doi.org/10.1186/1471-2350-6-11
PMid:15784141 PMCid:1084346
Holvoet P (2008). Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70: 193-219.
PMid:18669160
Hsueh WA and Bruemmer D (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43: 297-305.
http://dx.doi.org/10.1161/01.HYP.0000113626.76571.5b
PMid:14732733
Hu Q, Zhang XJ, Liu CX, Wang XP, et al. (2010). PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice. J. Vasc. Res. 47: 69-79.
http://dx.doi.org/10.1159/000235927
PMid:19729954
Issemann I and Green S (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650.
http://dx.doi.org/10.1038/347645a0
PMid:2129546
Iwai M, Kanno H, Senba I, Nakaoka H, et al. (2011). Irbesartan increased PPARgamma activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem. Biophys. Res. Commun. 406: 123-126.
http://dx.doi.org/10.1016/j.bbrc.2011.02.007
PMid:21296052
Ji Y, Liu J, Wang Z, Liu N, et al. (2009). PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab. Invest. 89: 887-902.
http://dx.doi.org/10.1038/labinvest.2009.45
PMid:19451898
Kagawa Y, Yanagisawa Y, Hasegawa K, Suzuki H, et al. (2002). Single nucleotide polymorphisms of thrifty genes for energy metabolism: evolutionary origins and prospects for intervention to prevent obesity-related diseases. Biochem. Biophys. Res. Commun. 295: 207-222.
http://dx.doi.org/10.1016/S0006-291X(02)00680-0
Kim KS, Choi SM, Shin SU, Yang HS, et al. (2004). Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 53: 1538-1543.
http://dx.doi.org/10.1016/j.metabol.2004.06.019
PMid:15562396
Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, et al. (2003). Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J. Clin. Endocrinol. Metab. 88: 1717-1722.
http://dx.doi.org/10.1210/jc.2002-020603
PMid:12679463
Liu L, Liu L, Ding Y, Huang Z, et al. (2001). Ethnic and environmental differences in various markers of dietary intake and blood pressure among Chinese Han and three other minority peoples of China: results from the WHO Cardiovascular Diseases and Alimentary Comparison (CARDIAC) Study. Hypertens. Res. 24: 315-322.
http://dx.doi.org/10.1291/hypres.24.315
PMid:11409657
Masud S and Ye S (2003). Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 40: 773-780.
http://dx.doi.org/10.1136/jmg.40.10.773
PMid:14569127 PMCid:1735275
McDermott MM (2007). The international pandemic of chronic cardiovascular disease. JAMA 297: 1253-1255.
http://dx.doi.org/10.1001/jama.297.11.1253
PMid:17374819
Meirhaeghe A, Fajas L, Helbecque N, Cottel D, et al. (2000). Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 24: 195-199.
http://dx.doi.org/10.1038/sj.ijo.0801112
PMid:10702770
Miyazaki Y, Mahankali A, Matsuda M, Glass L, et al. (2001). Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24: 710-719.
http://dx.doi.org/10.2337/diacare.24.4.710
PMid:11315836
Moran CS, Cullen B, Campbell JH and Golledge J (2009). Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J. Vasc. Res. 46: 209-217.
http://dx.doi.org/10.1159/000163019
PMid:18931513
Mori H, Ikegami H, Kawaguchi Y, Seino S, et al. (2001). The Pro12 →Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50: 891-894.
http://dx.doi.org/10.2337/diabetes.50.4.891
PMid:11289058
Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, et al. (1998). Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 251: 195-198.
http://dx.doi.org/10.1006/bbrc.1998.9421
PMid:9790929
Pan XF, Song XB, Wang LL, Li LX, et al. (2009). Association of the Pro12Ala polymorphism in peroxisome proliferators activated receptor-gamma gene with rheumatoid arthritis in Sichuan Province of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26: 87-90.
PMid:19199260
Ren Y, Sun C, Sun Y, Tan H, et al. (2009). PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul. Pharmacol. 51: 169-174.
http://dx.doi.org/10.1016/j.vph.2009.06.004
PMid:19540934
Ridker PM, Cook NR, Cheng S, Erlich HA, et al. (2003). Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23: 859-863.
http://dx.doi.org/10.1161/01.ATV.0000068680.19521.34
PMid:12663371
Rose GA and Blackburn H (1982). Cardiovascular Survey Methods. World Health Organization. WHO Monograph Series, Geneva.
Schaffler A, Barth N, Schmitz G, Zietz B, et al. (2001). Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine. 14: 369-373.
http://dx.doi.org/10.1385/ENDO:14:3:369
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, et al. (2006). Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch. Med. Res. 37: 736-743.
http://dx.doi.org/10.1016/j.arcmed.2006.01.009
PMid:16824933
Tamori Y, Masugi J, Nishino N and Kasuga M (2002). Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51: 2045-2055.
http://dx.doi.org/10.2337/diabetes.51.7.2045
PMid:12086932
Tavares V, Hirata RD, Rodrigues AC, Monte O, et al. (2005). Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 7: 605-611.
http://dx.doi.org/10.1111/j.1463-1326.2004.00453.x
PMid:16050954
Wang G, Wei J, Guan Y, Jin N, et al. (2005). Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54: 590-597.
http://dx.doi.org/10.1016/j.metabol.2004.11.017
PMid:15877288
Wei Q, Jacobs DR, Jr., Schreiner PJ, Siscovick DS, et al. (2006). Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA Study. J. Mol. Med. 84: 955-965.
http://dx.doi.org/10.1007/s00109-006-0088-7
PMid:16955276
Yamamoto Y, Hirose H, Miyashita K, Nishikai K, et al. (2002). PPAR(gamma)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51: 1407- 1409.
http://dx.doi.org/10.1053/meta.2002.35586
PMid:12404189
Yen CJ, Beamer BA, Negri C, Silver K, et al. (1997). Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem. Biophys. Res. Commun. 241: 270-274.
http://dx.doi.org/10.1006/bbrc.1997.7798
PMid:9425261
Zafarmand MH, van der Schouw YT, Grobbee DE, de Leeuw PW, et al. (2008). Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses. Vasc. Health Risk Manag. 4: 427-436.
PMid:18561518 PMCid:2496990